Benefits of Testosterone Replacement Therapy in Hypogonadal Males

Article Figures & Data

Table 1.

Patient Demographics Before and After Propensity Matching

		Before Propensity Matching				After Propensity Matching
Cohort	Demographics	Mean ± SD	Patients	% of Cohort	P-value	Mean ± SD	Patients	% of Cohort	P-value
1	Male sex		68,448	100	–		66,792	100	–
2	Male sex		95,008	100			66,792	100
1	Age at index	56.6 ± 9.8	68,448	100	<0.001	56.7 ± 9.8	66,792	100	0.013
2	Age at index	57.4 ± 10.3	95,008	100		56.8 ± 10.0	66,792	100
1	White		54,326	79.4	<0.001		52,777	79.0	0.809
2	White		71,724	75.5			52,741	79.0
1	Not Hispanic or Latino		48,285	70.5	<0.001		46,797	70.1	0.862
2	Not Hispanic or Latino		62,407	65.7			46,826	70.1
1	Unknown ethnicity		17,364	25.4	<0.001		17,208	25.8	0.535
2	Unknown ethnicity		27,735	29.2			17,109	25.6
1	Unknown race		7,819	11.4	<0.001		7,770	11.6	0.308
2	Unknown race		13,099	13.8			7,651	11.5
1	Black or African American		5,062	7.4	<0.001		5,024	7.5	0.010
2	Black or African American		8,077	8.5			5,274	7.9
1	Hispanic or Latin		2,799	4.1	<0.001		2,787	4.2	0.341
2	Hispanic or Latin		4,866	5.1			2,857	4.3
1	Asian		894	1.3	<0.001		894	1.3	0.030
2	Asian		1,653	1.7			805	1.2
1	American Indian or Alaska Native		190	0.3	0.005		171	0.3	0.785
2	American Indian or Alaska Native		198	0.2			166	0.2
1	Native Hawaiian or Other Pacific Islander		157	0.2	0.103		156	0.2	0.955
2	Native Hawaiian or Other Pacific Islander		257	0.3			155	0.2

Table 2.

Preexisting Conditions Associated with Mortality Before and After Propensity Matching

			Before Propensity Matching			After Propensity Matching
Cohort	I-10	Condition	Patients	% of Cohort	P-value	Patients	% of Cohort	P-value
1	I10-I16	Hypertensive diseases	31,527	46.1	<0.001	29,941	44.8	0.010
2	I10-I16	Hypertensive diseases	34,736	36.6		30,409	45.5
1	E08-E13	Diabetes mellitus	15,137	22.1	<0.001	14,304	21.4	0.009
2	E08-E13	Diabetes mellitus	17,220	18.1		14,697	22.0
1	E66	Overweight & obesity	13,768	20.1	<0.001	12,367	18.5	0.366
2	E66	Overweight & obesity	12,804	13.5		12,239	18.3
1	I20-I25	Ischemic heart diseases	8,081	11.8	<0.001	7,815	11.7	0.037
2	I20-I25	Ischemic heart diseases	10,086	10.6		8,062	12.1
1	N17-N19	Acute kidney failure & chronic kidney disease	5,689	8.3	<0.001	5,319	8.0	0.992
2	N17-N19	Acute kidney failure & chronic kidney disease	6,098	6.4		4,320	8.0
1	I50	Heart failure	2,765	4.0	<0.001	2,639	3.9	0.544
2	I50	Heart failure	3,209	3.4		2,595	3.9
1	C34	Malignant neoplasm of bronchus & lung	280	0.4	0.080	280	0.4	0.439
2	C34	Malignant neoplasm of bronchus & lung	262	0.4		262	0.4
1	I46	Cardiac arrest	137	0.2	<0.001	110	0.2	0.405
2	I46	Cardiac arrest	107	0.1		98	0.1

Abbreviation: ICD-10, International Statistical Classification of Diseases, Tenth Revision.

Table 3.

Mortality, Cardiovascular, and Prostate Cancer 3-Year Outcomes After Propensity Score Matching

Outcome	ICD-10	Cohort 1 (Prescribed T)	Cohort 2 (Not Prescribed T)	Risk Ratio	95% CI	P-value
Mortality	–	0.031	0.036	0.886	(0.836, 0.939)	<0.001
AF	I48	0.036	0.040	0.900	(0.851, 0.951)	<0.001
Stroke	I63	0.016	0.018	0.898	(0.826, 0.975)	0.011
MI	I21	0.018	0.019	0.977	(0.903, 1.057)	0.559
PC	C61	0.019	0.029	0.648	(0.603, 0.695)	<0.001

Abbreviations: ICD-10, International Statistical Classification of Diseases, Tenth Revision; T, testosterone; AF, atrial fibrillation; MI, myocardial infarction; PC, prostate cancer.

Table 4.

Mortality, Cardiovascular, and Prostate Cancer 3-Year Outcomes Before Propensity Score Matching

Outcome	ICD-10	Cohort 1 (Prescribed T)	Cohort 2 (Not Prescribed T)	Risk Ratio	95% CI	P-value
Mortality	–	0.032	0.034	0.940	(0.890, 0.991)	0.023
AF	I48	0.036	0.042	0.873	(0.830, 0.918)	<0.001
Stroke	I63	0.016	0.017	0.915	(0.848, 0.988)	0.023
MI	I21	0.019	0.018	1.032	(0.960, 1.110)	0.392
PC	C61	0.019	0.033	0.575	(0.539, 0.614)	<0.001

Abbreviations: ICD-10, International Statistical Classification of Diseases, Tenth Revision; T, testosterone; AF, atrial fibrillation; MI, myocardial infarction; PC, prostate cancer; CI, Class interval.